Accelerating Topical Drug Development Through Initial Excipient Selection

See the poster presented by Seppic at DDF Summit in Berlin in June 2023:

Introduction

Novel topical drug development will require multiple formulation adjustments from the initial formulation studies to the registration phase [1].

Common issues encountered are API chemical instability, API lack of solubility, dosage form instability, optimization of the skin delivery, mitigation of side-effects.

pH adjustment and change of nature or concentration of solvents, penetration enhancers and emollients can be relevant adjustments [2]. However, each adjustment is at risk of disrupting polymeric and surfactant systems, causing further delay in formulation and drug development [3].

There is a need for stabilizing excipients able to provide the same performance independently from formulation changes.

Material & Method

Thickening / Stabilizing Polymer
Acrylamide / Sodium Acryloyldimethyl Taurate Copolymer in inverse emulsion

Stability to formulation adjustments

Impact of pH adjustment on the polymer network

Authors: Benjamin GAVINET, Benoît SOUYRI, Emilie TONGLET, Maïté CAVAILLÈS, Alice DANESHVAR

See the full poster on “Accelerating Topical Drug Development Through Initial Excipient Selection” here

(click the picture to download the poster)

Source: Seppic poster “Accelerating Topical Drug Development Through Initial Excipient Selection”

SEPPIC Contact MAP

Do you need more information or a sample of excipients by Seppic?